Impact of IL28B Genotype on the Early and Sustained Virologic Response in Treatment-Naïve Patients With Chronic Hepatitis C

Stättermayer, Albert Friedrich; Stauber, Rudolf; Hofer, Harald; Rutter, Karoline; Beinhardt, Sandra; Scherzer, Thomas–Matthias; Zinober, Kerstin; Datz, Christian; Maieron, A; Dulic-Lakovic, E; Kessler, Harald H.; Steindl–Munda, Petra; Straßer, Michael; Krall, Christoph; Ferenci, Péter

doi:10.1016/j.cgh.2010.07.019

Cited by 158 publications

(185 citation statements)

References 33 publications

Supporting

Mentioning

149

Contrasting

Unclassified

Order By: Relevance

“…This is in contrast to genotype 1 HCV patients in whom SVR is significantly associated with rs12979860 irrespective of the RVR status. 34 Scherzer et al from Austria did not find any significant association of IL28B polymorphisms rs12979860 and rs8099917 with SVR in genotype 3 HCV-infected patients. 24 However, early response to treatment was significantly associated with the two SNPs, with the CC genotype and TT genotype, respectively, favoring a faster viral decline during weeks 2-4 of therapy.…”

Section: Discussionmentioning

confidence: 99%

Association of IL28B single nucleotide polymorphism rs8099917 with response to treatment in genotype 3 HCV-infected patients from India

Chinnaswamy¹

2014

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Association of IL28B single nucleotide polymorphism rs8099917 with response to treatment in genotype 3 HCV-infected patients from India

Chinnaswamy¹

2014

View full text Add to dashboard Cite

show abstract

“…In a study by Sarrazin et al (17), SVR was achieved in 85%, 58%, and 46% of patients with the C/C, C/T and T/T IL28B genotypes, respectively. In the group of patients from the Stättermayer study (18), the SVR rate was 79.1% in the C/C genotype vs. 43.2% in patients with T/T genotype. In our group, similar results were obtained: a 73.1% SVR rate in patients of genotype C/C, 40.9% in patients of genotype C/T, and 57.1% in patients of genotype T/T (or 73.1% in C/C vs. 43.7% in non-C/C patients; P = 0.0126).…”

Section: Discussionmentioning

confidence: 99%

The Correlation of Il28B Genotype With Sustained Virologic Response In Romanian patients With Chronic Hepatitis C

Sporea¹,

Popescu²,

Curescu³

et al. 2012

Hepat Mon

View full text Add to dashboard Cite

Background: Multiple variables influencing the sustained virologic response (SVR) in chronic hepatitis C have been evaluated. One of them is genetic polymorphism near the IL28B gene. Objectives: The aim of this study was to evaluate the influence of IL28B genotypes on SVR rates in a group of patients with chronic hepatitis C from the western part of Romania. Patients and Methods: A retrospective study was performed in 107 consecutive patients, previously treated with standard-of-care medication for chronic hepatitis C, identified from the databases of 2 centers. Patient demographics, viral load before treatment and at 12, 24, and 72 weeks from the treatment start, and IL28B genotype were evaluated. Results: Among the 107 patents in the study group, 54 patients had SVR (50.5%), and 62 (57.9%) showed a complete early virologic response (cEVR). The SVR rates according to IL28B genotype were as follows: 73.1% in patients with genotype C/C, 40.9% in those with genotype C/T, and 57.1% in those with genotype T/T (i.e., 73.1% among patients with the C/C genotype vs. 43.7% among those with non-C/C genotypes; P = 0.0126). The cEVR rates were 80.8% in patients with the C/C genotype vs. 51.2% in those with non-C/C genotypes (P = 0.011). Conclusions: In our cohort of 107 Caucasian HCV patients, the SVR rate was 50.5% with standard-of-care treatment. The SVR rate was directly related to the IL28B genotype: 73.1% in the C/C genotype vs. 43.7% in non-C/C genotypes (P = 0.0126).

show abstract

“…36 Stattermayer et al have shown that in contrast to genotypes 1 and 4, the IL28 gene polymorphisms had no impact on SVR rates in genotype 2/3. 33 However, recent other studies from Germany, Taiwan, and Japan have shown association of IL28B genotype with SVR. [37][38][39] (b) The value of IL28B polymorphisms testing in this population may be for patients who do not ∼55% in European-American patients, and ∼25% in AfricanAmerican patients.…”

Section: Chronic Hepatitis C: Non-genotypementioning

confidence: 99%

Interleukin 28B Polymorphisms and Hepatitis C—Translating the Association into Clinical Decision Making

Puri

2011

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

Host genetic factors have long been suspected to play a role in predicting outcome and treatment response in hepatitis C virus (HCV) infection. This was confirmed recently by three landmark genome-wide association studies (GWAS) published in 2009, which identified single nucleotide polymorphisms near the interleukin (IL) 28B region that were more common in responders to treatment. There has subsequently been rapidly increasing data regarding the significance of the IL28B polymorphism not only in response to therapy but also in spontaneous clearance of acute HCV infection. This clinical association of Il28B genotype with HCV may lead to personalized HCV therapy, where the clinician may tailor the duration and type of therapy for an individual patient. This review summarizes the available data on the impact of IL28B polymorphisms on HCV infection and discusses the possible approach to translate this association into clinical decision making for the treatment of HCV infection.

show abstract

Impact of IL28B Genotype on the Early and Sustained Virologic Response in Treatment-Naïve Patients With Chronic Hepatitis C

Cited by 158 publications

References 33 publications

Association of IL28B single nucleotide polymorphism rs8099917 with response to treatment in genotype 3 HCV-infected patients from India

Association of IL28B single nucleotide polymorphism rs8099917 with response to treatment in genotype 3 HCV-infected patients from India

The Correlation of Il28B Genotype With Sustained Virologic Response In Romanian patients With Chronic Hepatitis C

Interleukin 28B Polymorphisms and Hepatitis C—Translating the Association into Clinical Decision Making

Contact Info

Product

Resources

About